Overview

Innoviva (NASDAQ: INVA) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK.

Royalties Earned

chart

Press Releases

Date Title and Summary
Toggle Summary Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer
Hulme to execute capital allocation review and cost cutting initiatives of the board; will also oversee investigation into conduct of advisors to the board in connection with 2017 proxy contest BRISBANE, Calif. --(BUSINESS WIRE)--May 22, 2018-- Innoviva, Inc.
Toggle Summary Innoviva Reports First Quarter 2018 Financial Results
Royalties earned rose 28% to $55.8 million compared with the first quarter of 2017. Net income attributable to Innoviva stockholders increased 76% from the first quarter of 2017 to $29.6 million , or $0.29 per basic share. BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 26, 2018-- Innoviva, Inc.
Toggle Summary Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD
LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 24, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration ( FDA ) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol
Toggle Summary Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD
Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 18, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc.
Presentations & Events
There are currently no events to display.

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.